Sep. 20, 2024
Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat, and prevent hearing loss disorders, announced new positive medical data from its clinical programs, SENS-501 and SENS-401, during a symposium at the 36th World Congress of Audiology (WCA) in Paris, held at CNIT, La Défense, France. The company presented data from